CardioRenal Systems is a Milford, Massachusetts medical device company developing RenalPro (marketed as RenalGuard outside the US), an automated fluid-management system that prevents acute kidney injury in high-risk hospital settings. By monitoring urine output in real time and matching IV hydration in milliliter increments, the system keeps patients balanced during cardiac surgery, catheter procedures, and ICU care. RenalPro holds FDA Breakthrough Device Designation and a CE Mark, and in a 220-patient randomized UK trial cut AKI by 52% versus standard care.
Ilya Budik is the CEO of CardioRenal Systems, a Milford, Massachusetts medical device company behind the RenalPro System (sold as RenalGuard outside the U.S.), a technology built to prevent acute kidney injury in cardiac surgery, interventional cardiology, and ICU patients. A medtech executive with roughly a decade of experience across strategy, finance, and business development, he has steered the company through FDA Breakthrough Device Designation, CE Mark approval abroad, and an FDA IDE approval clearing the way for a U.S. pivotal trial. He previously led the neurodiagnostics company NeuroQuest and worked in innovation strategy and healthcare finance.